Anti-MAG Neuropathy PBMC

Anti-MAG Neuropathy PBMC for Autoimmune Demyelinating Neuropathy Research

Anti-MAG Neuropathy PBMC products are sourced from IRB-consented donors clinically diagnosed with anti-MAG neuropathy and processed under stringent conditions within 24 hours of collection. Anti-MAG neuropathy is an autoimmune peripheral neuropathy in which a monoclonal IgM autoantibody binds myelin-associated glycoprotein (MAG) in peripheral nerve myelin, producing a chronic, predominantly demyelinating and often distal, sensory-predominant neuropathy. These cryopreserved peripheral blood mononuclear cells give access to the clonal B-cell population that produces the pathogenic IgM.

Disease Biology and Why PBMC

• IgM anti-MAG autoantibody is the defining feature; it is typically produced by a clonal B-cell or plasma-cell population, frequently in the setting of an IgM monoclonal gammopathy (MGUS) or, less often, Waldenström macroglobulinaemia.
• Clonal B cells are the therapeutic target: PBMCs allow identification, sorting, and immunoglobulin gene sequencing of the responsible clone, which is not possible from acellular matrices.
• B-cell depletion research: rituximab and other anti-CD20 or BTK-directed strategies aim at this clone; PBMCs support target expression, depletion, and repopulation studies.
• Complement-dependent myelin injury: anti-MAG IgM deposition with complement activation causes widening of myelin lamellae, linking B-cell output to the pathological lesion.
• Repertoire and clonality analysis: BCR sequencing and MYD88 L265P assessment in the B-cell compartment are informative for classifying the underlying lymphoproliferative process.
• T-cell and innate compartments can be profiled in parallel to study help for clonal IgM production and comparison with other inflammatory neuropathies.

Donor Stratification Available

• Anti-MAG IgM titre where available
• Underlying haematological context: IgM MGUS, Waldenström macroglobulinaemia, or no detectable paraprotein
• Monoclonal protein isotype and light chain
• Clinical severity and pattern: sensory-predominant, sensorimotor, or with prominent ataxia or tremor
• Treatment status: rituximab or other anti-CD20 therapy, BTK inhibitor, chemoimmunotherapy, IVIg, or treatment-naive
• Disease duration and time since diagnosis
• Matched healthy controls available

Product Features

• Research Use Only (RUO), cryopreserved PBMCs
• Clinically confirmed anti-MAG neuropathy donors
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• IRB-approved protocols and electronic informed consent
• Custom aliquots available upon request

De-identified Donor Data

• Verified anti-MAG neuropathy diagnosis
• Anti-MAG antibody and paraprotein results where available
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported allergies and infectious disease history
• Additional anti-MAG neuropathy-specific data available upon request

Applications

• Clonal B-cell identification, sorting, and immunophenotyping by flow or mass cytometry
• B-cell receptor repertoire sequencing and clonality analysis
• Single-cell RNA sequencing and bulk transcriptomic profiling
• B-cell depletion and BTK inhibitor target validation
• Autoantibody-producing cell characterisation and in vitro IgM secretion assays
• Immune pathway analysis in demyelinating neuropathy
• Genomic DNA extraction for MYD88 and related variant analysis
• Biomarker discovery, drug screening, and therapeutic development

Other Anti-MAG Neuropathy Specimen Types

Anti-MAG neuropathy donor material is also available as Anti-MAG Neuropathy Serum, Anti-MAG Neuropathy Plasma, and Anti-MAG Neuropathy Whole Blood. Serum and plasma are the appropriate matrices for anti-MAG IgM titration.

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11 – compliant e-consent system
• HIPAA-compliant donor data protection

Ordering & Customization

Anti-MAG Neuropathy PBMC samples are shipped on dry ice and available in standard or custom aliquots. For pricing, international orders, or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. Browse all human PBMCs or request a custom disease-state collection.